Table 2.
Efficacy results between different randomized controlled trials
| Population1 | HR | ||
|---|---|---|---|
| NSCLC 1st line | |||
| Keynote-042 vs. CheckMate-026 | Pembrolizumab vs Nivolumab | PDL-1≥1% | 0.81 (0.63-1.05) |
| Keynote-042 vs. Impower-110 | Pembrolizumab vs. Atezolizumab | PDL-1≥1% | 1.04 (0.79-1.38) |
| CheckMate-026 vs. Impower-110 | Nivolumab vs. Atezolizumab | PDL-1≥1% | 1.29 (0.92-1.79) |
| Keynote-042 + Kenote-024 vs. CheckMate-026 | Pembrolizumab vs Nivolumab | PDL-1≥50% | 0.74 (0.50-1.11) |
| Keynote-042 + Kenote-024 vs Impower-110 | Pembrolizumab vs. Atezolizumab | PDL-1≥50% | 1.13 (0.73-1.76) |
| CheckMate-026 vs Impower-110 | Nivolumab vs. Atezolizumab | PDL-1≥50% | 1.52 (0.89-2.60) |
| NSCLC 2nd line | |||
| Keynote-010 vs CheckMate-017 + CheckMate-057 | pembrolizumab vs Nivolumab | PDL-1≥1% | 1.01 (0.82-1.25) |
| Keynote-010 vs OAK + POPLAR | Pembrolizumab vs. atezolizumab | PDL-1≥1% | 1.00 (0.78-1.29) |
| Keynote-010 vs Javelin lung 200 | Pembrolizumab vs. avelumab | PDL-1≥1% | 0.77 (0.61-0.96) |
| Checkmate-017 + Checkmate-057 vs OAK + POPLAR NSCLC 2nd line | Nivolumab vs. atezolizumab | PDL-1≥1% | 0.99 (0.76-1.28) |
| CheckMate-017 + Checkmate-057 vs Javelin Lung 200 line PDL1>1% | Nivolumab vs. avelumab | PDL-1≥1% | 0.76 (0.58-0.98) |
| OAK + POPLAR vs Javelin Lung 200 | Atezolizumab vs. avelumab | PDL-1≥1% | 0.77 (0.58-1.01) |
| Keynote-010 vs Checkmate-017 + Checkmate-057 | Pembrolizumab vs. nivolumab | PDL-1≥50% | 1.32 (0.81-2.16) |
| Keynote-010 vs OAK + POPLAR | Pembrolizumab vs. atezolizumab | PDL-1≥50% | 1.23 (0.78-1.94) |
| Keynote-010 vs Javelin Lung 200 NSCLC PDL1>50 % | Pembrolizumab vs. avelumab | PDL-1≥50% | 0.79 (0.55-1.13) |
| Checkmate-017 + Checkmate-057 vs. OAK + POPLAR | Nivolumab vs. atezolizumab | PDL-1≥50% | 0.93 (0.52-1.76) |
| Checkmate-017 + Checkmate-057 vs. Javelin Lung 200 | Nivolumab vs. avelumab | PDL-1≥50% | 0.60 (0.36-0.99) |
| OAK + POPLAR vs Javelin Lung 200 | Atezolizumab vs. avelumab | PDL-1≥50% | 0.64 (0.40-1.03) |
| Checkmate-017 + Checkmate-057 vs OAK + POPLAR | Nivolumab vs. atezolizumab | Unselected for PDL-1 | 0.86 (0.62-1.19) |
| Metastatic melanoma 1st line | |||
| Keynote-006 vs Checkmate-067 Total population | Pembrolizumab vs. nivolumab | Unselected for PDL-1 | 1.16 (0.89-1.51) |
| Keynote-006 vs Checkmate-067 | Pembrolizumab vs. nivolumab | PDL-1<1% | 1.32 (0.67-2.59) |
| Keynote-006 vs Checkate-067 | Pembrolizumab vs. nivolumab | PDL-1≥1% | 1.09 (0.71-1.67) |
| Metastatic urothelial ca 2nd line | |||
| Keynote-045 vs Imvigor211 | Pembrolizumab vs. atezolizumab | Unselected for PDL-1 | 0.89 (0.69-1.15) |
| Keynote-045 vs Imvigor211 | Pembrolizumab vs. atezolizumab | PDL-1≥1% | 0.70 (0.47-1.05) |
| Metastatic HNSCC 1st line | |||
| Keynote-048 vs Checkmate-141 | Pembrolizumab vs. nivolumab | Unselected for PDL-1 | 1.18 (0.83-1.68) |
| Keynote-048 vs Checkmate-141 | Pembrolizumab vs. nivolumab | PDL-1≥1% | 1.25 (0.76-2.06) |
1 PDL1 status based on the specific assay used in the respective trials.
HNSCC, head and neck squamous cell carcinoma.